Semaglutide myths usually start with one true detail stretched too far. Semaglutide isn't a steroid. Weight regain after stopping is common, but it isn't instant or universal. Human evidence has not shown that the medicine causes thyroid cancer or suicidal thoughts. And compounded semaglutide is not Wegovy. Here are ten familiar claims, each graded against what the evidence can actually support.
Semaglutide myths: how the grades work
Supported means the claim holds up as stated. Partly means one piece is right but the conclusion is too broad. Not supported means the cited evidence does not back the claim. Unknown means good data cannot settle it yet.
1. “Semaglutide is a steroid.”
Not supported: semaglutide is an engineered peptide, a short chain of amino acids, that acts like GLP-1, a gut hormone involved in blood sugar and appetite. Steroids have a different chemical structure and biology. The original semaglutide discovery paper describes how researchers modified a GLP-1 analogue so it would remain active long enough for weekly dosing. Calling it a steroid confuses two different drug families.
2. “All the weight comes straight back when you stop.”
Partly: regain was common, but neither “all” nor “straight back” matches the STEP 1 extension. In 327 participants, the semaglutide group had lost 17.3% before treatment stopped and regained 11.6 percentage points over the next year, leaving an average net loss of 5.6% from the starting weight (Wilding and colleagues, 2022). The STEP 1 results explain the original trial. As of September 18, 2026, the day this article was written, a randomized trial published online June 20, 2026 found that adults continuing semaglutide consumed about 270 fewer calories than placebo, an inactive comparison, at week 60, even though some self-reported appetite differences had faded. Feeling less appetite suppression does not by itself mean the medicine has stopped working.
3. “Semaglutide melts fat and nothing else.”
Not supported: in a 140-person STEP 1 body-composition substudy, fat mass fell 19.3% and lean mass fell 9.7% over 68 weeks; lean mass rose as a share of total weight because fat fell faster (Wilding and colleagues, 2021). The scan's lean measurement includes water, organs, connective tissue, and muscle, but excludes bone. It cannot be read as a direct measurement of muscle alone.
4. “Semaglutide causes thyroid cancer in people.”
Unknown: the current Wegovy prescribing information says semaglutide caused thyroid C-cell tumors in rodents and that the relevance to humans is unknown. It does not establish that semaglutide causes thyroid cancer in people. The boxed warning still matters: the label says the branded product should not be used by someone with a personal or family history of medullary thyroid carcinoma, a cancer of those C cells, or multiple endocrine neoplasia syndrome type 2, an inherited cancer syndrome.
5. “Semaglutide causes suicidal thoughts.”
Not supported: on January 13, 2026, the Food and Drug Administration (FDA) reported that its review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines. Its analysis combined 91 trials that compared a medicine with an inactive treatment and covered 107,910 people; the agency asked manufacturers to remove the warning from affected labels. That population finding does not make an individual mood change unimportant; new suicidal thoughts are always urgent.
6. “Compounded semaglutide is the same as Wegovy.”
Not supported: Wegovy is a branded finished product; a compounded prescription is prepared for an individual patient and may differ in formulation, concentration, container, and delivery device. Semaglutide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA says compounded drugs do not receive its review for safety, effectiveness, or quality before marketing. The brand-versus-molecule explanation goes deeper. A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and the doctor.
7. “You can't drink alcohol while taking semaglutide.”
Not supported as an absolute: current semaglutide prescribing information does not list alcohol as a direct interaction. Alcohol can still overlap with nausea, vomiting, dehydration, low blood sugar risk for people also taking insulin or a sulfonylurea, an older type of diabetes medicine, and pancreatitis risk when drinking is heavy. That is why the answer depends on the person and the rest of the medication list. The full semaglutide and alcohol guide covers those separate risks.
8. “Semaglutide is only for people with diabetes.”
Not supported: semaglutide products have different labels. Ozempic is used in type 2 diabetes, while the current Wegovy label includes long-term weight reduction for qualifying adults and adolescents with obesity, and for certain adults with overweight and a weight-related condition. A drug's molecule does not tell you which product, indication, or patient is being discussed.
9. “The semaglutide pill works exactly like the shot.”
Partly: tablets and injections can contain the same active molecule and act at the same biological target, but the route and schedule are not interchangeable. The current Wegovy label describes a daily tablet and a weekly injection as separate regimens. The OASIS 4 trial studied a 25 mg oral dose against an inactive treatment; it was not a head-to-head test against the weekly shot, so it cannot prove identical results. Our pill-versus-injection guide explains the practical differences.
10. “Natural semaglutide supplements exist.”
Not supported: semaglutide is a specific engineered prescription peptide, not a vitamin, herb, or nutrient. A supplement may claim to support the body's own GLP-1 response, but that does not make it semaglutide or establish that it produces the same exposure or outcomes. Similar marketing words do not turn a supplement into the medicine studied in semaglutide trials.
What the grades mean for treatment
A myth can point toward a real question without answering it. Regain after withdrawal, lean-mass change, thyroid history, mood, alcohol use, and dosage form all belong in a clinical discussion. Tirzepatide may also come up, but it is a different prescription medicine. Considering it is a separate treatment decision, not a way to sidestep semaglutide facts.
Why the prescription route matters
At Promise, a licensed provider reviews every request, and not everyone qualifies. That review connects the evidence to medical history, current medicines, the exact formulation, and follow-up. It also leaves room for the honest answer these myths often avoid: sometimes the evidence says partly, and sometimes it still says unknown.
